Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

In Vivo Quantification of Human Serotonin 1A Receptor Using 11C-CUMI-101, an Agonist PET Radiotracer

Matthew S. Milak, Christine DeLorenzo, Francesca Zanderigo, Jaya Prabhakaran, J.S. Dileep Kumar, Vattoly J. Majo, J. John Mann and Ramin V. Parsey
Journal of Nuclear Medicine December 2010, 51 (12) 1892-1900; DOI: https://doi.org/10.2967/jnumed.110.076257
Matthew S. Milak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine DeLorenzo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Zanderigo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaya Prabhakaran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.S. Dileep Kumar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vattoly J. Majo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. John Mann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramin V. Parsey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    11C-CUMI binding. (Top) MR images of subject. (Middle) Sum of last 60 min (6 frames) of PET acquisition. (Bottom) BPF value of every voxel within brain slices (calculated using EBEGA), with color bar indicating values of BPF data shown.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Hippocampal time–activity curve fits. On left side, 2TC (iterative, 2TC; noniterative, 2TCNI; constrained, 2TCC) model fits are indicated. Raw data are shown with diamonds. On right side, raw data are shown (◆) transformed into space used for graphical interpretation. Cp is concentration of ligand in plasma, and CROI is concentration of ligand in hippocampus. 1TC = 1 tissue compartment; 1TC-NI = 1 tissue compartment, noniterative; SUV = standardized uptake value.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    BPF TS. BPF was calculated using 5 models at 6 scan durations. For each region, percentage of total scans (n = 14) in which calculated BPF was within 5% of BPF calculated at 120 min was determined. This plot shows average of these percentages over all regions tested. Error bars indicate SD. Constr = constrained.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    LEGA BPND with plasma input, compared with BPND values calculated by RR approaches. All high-binding ROIs listed in Table 1 are included. Identity lines are plotted (dashed lines) for reference.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Comparison of ROI and voxel analysis. VT (left) and BPND (right) values as found by ROI analysis vs. average of all voxels within ROI as found using voxel analysis. Identity lines are plotted (dashed lines) for reference.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    VT TS. VT values were calculated using LEGA and scan times ranging from 70 to 120 min. At each time period, percentage error between regional VT at that scan duration and VT calculated using 120 min of scan duration was calculated and averaged. Error bars are omitted for clarity. CGM = cerebellar gray matter; ENT = entorhinal cortex; HIP = hippocampus; INS = insula.

Tables

  • Figures
    • View popup
    TABLE 1

    Metrics on High-Binding ROIs Using 120-Minute Scan and LEGA

    ROIAverage BPF of each ROI (mL/cm3)PD (%)WSMSS (mL/cm3)ICC (unitless)SD (%)Identifiability (mL/cm3)
    Entorhinal cortex*32.623.86 ± 12.426.320.8720.794.68
    Hippocampus31.666.85 ± 5.983.900.9018.864.70
    Insula28.615.44 ± 11.425.500.6413.273.42
    Posterior parahippocampal gyrus*26.102.37 ± 9.523.220.8617.483.28
    Temporal lobe*25.507.82 ± 10.143.790.7916.012.99
    Amygdala21.206.25 ± 9.793.160.9025.453.09
    Cingulate*18.480.33 ± 14.422.580.7717.651.85
    Medial prefrontal cortex*17.147.09 ± 11.682.370.6715.331.69
    Orbital prefrontal cortex*14.8718.34 ± 22.735.350.5923.841.53
    Parietal lobe*14.064.40 ± 10.971.160.7013.591.28
    Dorsolateral prefrontal cortex*13.6910.20 ± 13.892.320.5616.471.29
    Raphe12.4216.54 ± 19.262.960.8029.961.77
    Occipital lobe*9.708.25 ± 16.351.050.5515.400.90
    • ↵* Gray-matter–masked regions.

    • Average PD, WSMSS, ICC, %SD, and identifiability estimates are based on BPF measurements.

    • View popup
    TABLE 2

    Outcome Metrics Using 120-Minute Scan and BPF

    Metric2TC2TCCLogan analysisLEGA2TCNI
    PD (%)8.45 ± 15.178.32 ± 13.057.08 ± 14.627.52 ± 13.636.43 ± 16.53
    WSMSS (mL/cm3)7.00 ± 10.543.85 ± 1.693.32 ± 1.623.36 ± 1.607.78 ± 7.74
    ICC (unitless)0.65 ± 0.170.72 ± 0.160.74 ± 0.130.74 ± 0.130.68 ± 0.13
    SD (%)20.45 ± 6.3819.24 ± 4.2919.13 ± 5.9218.78 ± 4.9622.53 ± 7.38
    Identifiability (mL/cm3)2.73 ± 3.023.42 ± 3.322.64 ± 2.362.50 ± 2.393.31 ± 3.54
    • Mean ± SD across all subjects and all regions is shown. Models that attain best mean result in each category are in bold.

    • View popup
    TABLE 3

    Outcome Metrics Using 120-Minute Scan and BPP

    Metric2TC2TCCLogan analysisLEGA2TCNI
    PD (%)13.22 ± 13.6613.10 ± 11.3811.85 ± 13.2513.29 ± 12.3711.19 ± 15.16
    WSMSS (mL/cm3)0.81 ± 1.130.49 ± 0.260.42 ± 0.220.43 ± 0.230.78 ± 0.68
    ICC (unitless)0.61 ± 0.150.66 ± 0.160.70 ± 0.110.69 ± 0.110.65 ± 0.14
    SD (%)21.57 ± 5.9820.15 ± 3.9220.22 ± 5.5419.81 ± 4.5423.12 ± 6.15
    Identifiability (mL/cm3)0.82 ± 0.941.02 ± 0.990.79 ± 0.700.75 ± 0.710.99 ± 1.05
    • Mean ± SD across all subjects and all regions is shown. Models that attain best mean result in each category are in bold.

    • View popup
    TABLE 4

    Metrics on High-Binding ROIs Using 120-Minute Scan and LEGA

    ROIAverage VT of each ROI (mL/cm3)PD (%)WSMSS (mL/cm3)ICC (unitless)SD (%)Identifiability (mL/cm3)
    Entorhinal cortex15.415.57 ± 8.751.090.8315.781.85
    Hippocampus15.177.28 ± 3.890.770.8715.281.88
    Insula14.256.23 ± 5.280.650.7711.451.52
    Posterior parahippocampal gyrus13.534.32 ± 4.810.410.9014.681.49
    Temporal lobe13.367.22 ± 6.270.730.7913.481.36
    Amygdala12.036.1 ± 4.950.450.9017.451.41
    Cingulate11.272.87 ± 5.470.220.9214.001.05
    Medial prefrontal cortex10.875.71 ± 5.420.350.8212.421.00
    Orbital prefrontal cortex10.219.05 ± 7.200.600.7213.840.94
    Parietal lobe9.954.05 ± 4.510.170.8811.410.86
    Dorsolateral prefrontal cortex9.856.31 ± 5.720.330.7912.370.87
    Raphe9.497.33 ± 7.590.400.8315.660.94
    Occipital lobe8.654.44 ± 6.800.210.7510.280.75
    CGM5.770.42 ± 4.800.040.9211.560.48
    • View popup
    TABLE 5

    Average and SD of Kinetic Rate Constants Using 120-Minute Scan and 2-TC Noniterative Method

    ROIK1k2k3k4
    Entorhinal cortex0.31 ± 0.180.08 ± 0.110.09 ± 0.100.03 ± 0.02
    Hippocampus0.34 ± 0.200.12 ± 0.110.13 ± 0.100.03 ± 0.01
    Insula0.39 ± 0.170.11 ± 0.080.12 ± 0.090.04 ± 0.02
    Posterior parahippocampal gyrus0.34 ± 0.160.08 ± 0.080.08 ± 0.070.04 ± 0.02
    Temporal lobe0.40 ± 0.240.10 ± 0.100.10 ± 0.060.05 ± 0.02
    Amygdala0.30 ± 0.170.07 ± 0.080.07 ± 0.090.03 ± 0.02
    Cingulate0.41 ± 0.190.11 ± 0.080.09 ± 0.050.05 ± 0.02
    Medial prefrontal cortex0.42 ± 0.200.10 ± 0.070.09 ± 0.060.06 ± 0.03
    Orbital prefrontal cortex0.39 ± 0.200.10 ± 0.090.08 ± 0.070.05 ± 0.02
    Parietal lobe0.44 ± 0.220.13 ± 0.100.10 ± 0.070.06 ± 0.02
    Dorsolateral prefrontal cortex0.41 ± 0.190.11 ± 0.080.09 ± 0.070.06 ± 0.02
    Raphe0.34 ± 0.210.11 ± 0.100.07 ± 0.080.04 ± 0.02
    Occipital lobe0.45 ± 0.230.15 ± 0.100.08 ± 0.060.05 ± 0.02
    CGM0.42 ± 0.220.15 ± 0.100.05 ± 0.030.05 ± 0.02
    • View popup
    TABLE 6

    Time–Stability Analysis of High-Binding ROIs Using LEGA

    Scan length (min)
    708090100110120
    ROIBPFVTBPFVTBPFVTBPFVTBPFVTBPFVT
    Entorhinal cortex36505057437150648686100100
    Hippocampus294357645764577179100100100
    Insula4343577186868686100100100100
    Posterior parahippocampal gyrus36295064577164797993100100
    Temporal lobe506443576471718693100100100
    Amygdala36504357437143717993100100
    Cingulate64645779718671100100100100100
    Medial prefrontal cortex64647171717971100100100100100
    Orbital prefrontal cortex505750795771578679100100100
    Parietal lobe797986937910093100100100100100
    Dorsolateral prefrontal cortex64646479647971100100100100100
    Raphe213621645079437171100100100
    Occipital lobe506457935093649393100100100
    • For each region, percentages of BPF or VT (of 14 PET scans) are indicated; values are estimated using indicated scan lengths, which fall within ±5% of BPF or VT values estimated using 120-min scan.

    • View popup
    TABLE 7

    Metrics for Bloodless Models Using 120-Minute Scan and BPND

    MetricSRTMBloodless Logan analysisBloodless LEGA
    PD (%)9.67 ± 11.6310.47 ± 11.3811.59 ± 17.35
    WSMSS (unitless)0.008 ± 0.0030.007 ± 0.0030.010 ± 0.006
    ICC (unitless)0.65 ± 0.130.59 ± 0.160.56 ± 0.16
    SD (%)15.68 ± 5.4414.93 ± 5.7415.75 ± 6.50
    Mean % bias−3.47 ± 3.60−7.32 ± 5.86−3.95 ± 7.31
    • Mean ± SD across all subjects and all regions is shown. Models that attain best average result in each category are in bold.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 51 (12)
Journal of Nuclear Medicine
Vol. 51, Issue 12
December 1, 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Vivo Quantification of Human Serotonin 1A Receptor Using 11C-CUMI-101, an Agonist PET Radiotracer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
In Vivo Quantification of Human Serotonin 1A Receptor Using 11C-CUMI-101, an Agonist PET Radiotracer
Matthew S. Milak, Christine DeLorenzo, Francesca Zanderigo, Jaya Prabhakaran, J.S. Dileep Kumar, Vattoly J. Majo, J. John Mann, Ramin V. Parsey
Journal of Nuclear Medicine Dec 2010, 51 (12) 1892-1900; DOI: 10.2967/jnumed.110.076257

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In Vivo Quantification of Human Serotonin 1A Receptor Using 11C-CUMI-101, an Agonist PET Radiotracer
Matthew S. Milak, Christine DeLorenzo, Francesca Zanderigo, Jaya Prabhakaran, J.S. Dileep Kumar, Vattoly J. Majo, J. John Mann, Ramin V. Parsey
Journal of Nuclear Medicine Dec 2010, 51 (12) 1892-1900; DOI: 10.2967/jnumed.110.076257
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Synthesis of Patient-Specific Transmission Data for PET Attenuation Correction for PET/MRI Neuroimaging Using a Convolutional Neural Network
  • 11C-CUMI-101, a PET Radioligand, Behaves as a Serotonin 1A Receptor Antagonist and Also Binds to {alpha}1 Adrenoceptors in Brain
  • Radiosynthesis and Preclinical Evaluation of 18F-F13714 as a Fluorinated 5-HT1A Receptor Agonist Radioligand for PET Neuroimaging
  • Plasma A{beta} and PET PiB binding are inversely related in mild cognitive impairment
  • SEP-225289 Serotonin and Dopamine Transporter Occupancy: A PET Study
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire